Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Recovery article

CJC-1295 and GHRP-2 Blend - Synergistic Potential on the GH-IGF-1 Axis

CJC-1295 and GHRP-2 Blend – Synergistic Potential on the GH-IGF-1 Axis Jul 29, 2025 Although each peptide has shown promise individually in raising GH—and, secondarily, insulin-like growth factor-1 (IGF-1)—levels in preclinical and early clinical studies, ther

By Recovery & Performance Peptides Editorial Team

CJC-1295 and GHRP-2 Blend – Synergistic Potential on the GH-IGF-1 Axis

Jul 29, 2025

Although each peptide has shown promise individually in raising GH—and, secondarily, insulin-like growth factor-1 (IGF-1)—levels in preclinical and early clinical studies, there remains considerable uncertainty about whether their mechanisms might intersect or even synergize when exposed to research models in combination. On one hand, GHRP‑2 and CJC‑1295 exploit separate GPCRs with divergent downstream signaling; on the other, both ultimately converge on the somatotroph’s secretory machinery. Exploring their combined exposure to research models in laboratory settings may further reveal additive or synergistic potential on GH pulsatility in laboratory settings.

Research

Structural Differences of CJC-1295 and GHRP-2

Researchers such as Jette et al. suggest that CJC-1295 is “a tetrasubstituted form of hGRF1–29 with an added Nε-3-maleimidopropionamide derivative of lysine at the C terminus”.(1) As a reference, hGRF 1–29 refers to the 29-amino acid N-terminal fragment of growth hormone-releasing hormone (GHRH), which corresponds to the biologically active portion of the full 44-residue GHRH responsible for stimulating growth hormone release. This truncated form is commonly exposed to research models for experimental purposes due to its preserved receptor activity.

This peptide features several specific amino acid substitutions and a chemical conjugation moiety, which may confer enhanced stability and pharmacokinetic properties. Specifically, CJC-1295 possesses a D-alanine substitution at the 2-position, which possibly supports resistance to enzymatic degradation by dipeptidylpeptidase-IV (DPP-IV), a primary enzyme implicated in the rapid clearance of endogenous GHRH peptides. Additional substitutions include a glutamine residue replacing asparagine at position 8, posited to reduce asparagine-related chemical rearrangements or hydrolysis, an alanine substitution at the 15-position hypothesized to increase bioactivity, and a leucine at position 27 to mitigate methionine oxidation, potentially.

Structurally speaking, CJC-1295 also carries a Nε-3-maleimidopropionic acid (MPA) moiety attached to an extra lysine residue introduced at the C-terminus beyond the endogenous 29 amino acids of hGRF. The maleimido group is crucial to this process because it facilitates covalent binding to the free thiol group of cysteine residue 34 on albumin in extravascular fluids. This plays a critical role in extending the peptide’s plasma residence time by reducing clearance and protecting it from proteolytic degradation. Specifically, as Jette et al. comment, the half-life of observed cell cultures may be extended by up to 72 hours.

In contrast, research by Berlanga-Acosta et al. suggests that GHRP-2 is a synthetic hexapeptide derived from other GHRPs, such as GHRP-6. Notably, the class of GHRPs is inspired by modifications of enkephalins, which are regularly occurring pentapeptides that function as endogenous opioids. Initial observations suggested that certain chemical analogs of enkephalin amide may contribute to the induction of growth hormone release. They may, by extension, support the hypothesis that modifications to the enkephalin structure may produce potent synthetic peptides with novel bioactivity. Thus, GHRP-2 might be considered an engineered sequence, possibly derived from or related to enkephalins, and specifically optimized to elicit growth hormone release instead of opioid actions.

Mechanisms of Action of CJC-1295 and GHRP-2 on Pituitary Cells

The structural difference between CJC-1295 and GHRP-2 also results in significantly different receptor affinities, despite both peptides being researched for their potential to increase GH synthesis in pituitary cells. Specifically, CJC-1295 appears to engage with the GHRH receptors, which normally respond to endogenous GHRH and are considered the main type of receptors mediating GH synthesis. Research by Culhane et al. suggests this may be a two‑stage process.(3)

In the first stage, the back end of CJC‑1295 might loosely latch onto the receptor’s outer domain, a region that apadles growth‑hormone–releasing peptides. Structural studies of similar receptors suggest this “docking” may involve the peptide’s helical segment slipping into a groove on the receptor’s surface. In a second step, the front end of CJC‑1295 potentially pokes deeper into the space between the receptor’s outer loops and its membrane‑spanning helices.

By making contact in this way, CJC-1295 may subtly alter the orientation of those helices, encouraging one helix (TM6) to swing outward. This movement is commonly posited to open up the receptor’s inner face, where it may then engage G proteins and trigger the cAMP signaling cascade that leads to GH release. Altogether, these ideas suggest that CJC‑1295 might act in much the same way as endogenous GHRH. Added modifications may potentially prolong its stay on the receptor and, therefore, extend its growth–hormone–releasing potential.

On the other hand, GHRP‑2 may engage the growth‑hormone secretagogue receptor (GHSR1a, also referred to as the ghrelin receptor) in a way that mirrors, but is not identical to, the way ghrelin itself binds. Research by Yin et al. suggests that GHSR1a is a seven‑transmembrane GPCR that presents a deep binding pocket formed largely by helices II, III, V, and VI.(4) It’s been posited that the C‑terminal end of GHRP‑2 first docks against key polar residues near the extracellular loops—perhaps involving contacts with Glu124 and surrounding charged side chains—much as other secretagogues do.

Once the peptide’s tail is loosely anchored, the N‑terminal segment of GHRP‑2 may then insert more fully into the crevice between the transmembrane helices, thereby permitting G‑protein coupling. This may lead to activation of phospholipase C (PLC). In this scenario, PLC would hydrolyze membrane phosphatidyl‑inositol 4,5‑bisphosphate (PIP₂) into two second messengers—inositol 1,4,5‑trisphosphate (IP₃) and diacylglycerol (DAG).

IP₃ might then diffuse through the cytosol to bind IP₃ receptors on the endoplasmic reticulum, triggering a release of stored Ca²⁺ into the cytoplasm and thereby elevating Ca²⁺ ion levels. Meanwhile, the locally generated DAG may remain in the membrane and possibly recruit and activate protein kinase C (PKC), which in turn might phosphorylate downstream targets that modulate both growth hormone exocytosis and gene transcription.

CJC-1295 and GHRP-2 Potential on the GH-IGF-1 Axis

As mentioned, both CJC-1295 and GHRP-2 are researched in the context of stimulating GH synthesis. GH acting on hepatic and other cells may also drive IGF‑1 gene transcription and secretion. IGF‑1 (insulin‑like growth factor‑1) is a peptide hormone that mediates many of GH’s growth‑promoting and metabolic potential.

Research on CJC-1295 by Teichman et al. suggests that CJC-1295 may boost “GH concentrations by 2- to 10-fold for 6 d or more”.(5) This elevation appeared to occur within 2 hours after exposure to the peptide, and the cells continued to produce elevated levels of GH for about 6 days. The area under the GH curve over the first week rose from ~758 ng·h/mL (30 µg/kg) to ~1,370 ng·h/mL (250 µg/kg)—suggesting about a 2‑ to 3‑fold greater overall GH release compared with unstimulated conditions. Consequently, the levels of the anabolic mediator IGF-1 were also elevated by 1.5- to 3-fold compared to baseline.

Research on GHRP-2 by Bowers et al. also suggests that the peptide may provoke a remarkably robust amplification of GH output, on the order of 6-fold above baseline secretion.(6) Specifically, the experiment involved a 24-hour continuous exposure to GHRP‑2 at a concentration of 1 µg/kg·h, which appeared to increase total daily GH secretion from roughly 20–30 µg·L⁻¹·24 h (placebo) to about 120–180 µg·L⁻¹·24 h. Furthermore, IGF‑1 rose from roughly 90–100 µg/L at baseline to about 150–160 µg/L after 24 hours of GHRP‑2 exposure and up to 180 µg/L after 30 days of exposure.

Data like this suggests that sustained GHRP-2 exposure may potentially increase IGF-1 production by 50–80%. Further research by Veldhuis et al. suggests that this increase is greater than that of GHRH analogs.(7) The peak increase in GH levels during 3 hours post-exposure reached up to +23.5 μg·L⁻¹. When compared to endogenous GHRH, this GH output was roughly 1.6 times higher than with GHRH.

Potential Synergism Between CJC-1295 and GHRP-2

Currently, no research simultaneously investigates the relative implications of CJC-1295 and GHRP-2 on GH synthesis. But the aforementioned research by Bowers et al. has investigated the potential of GHRP-2 when combined with the unmodified version of GHRH.(6)

The researchers involved commented that combined exposure to the two peptides over 24 hours may have contributed to an increase in 24-hour GH levels of between 238 ± 28 µg·L⁻¹ and 452 ± 106 µg·L⁻¹. This represents a 16-fold increase over the baseline levels of approximately 20–30 µg·L⁻¹. This is also more than double the response to GHRP‑2 alone. This pronounced synergy suggests that engaging both the ghrelin (GHS-R) and GHRH receptors simultaneously may unlock an amplified GH secretory burst.

A second experiment by Veldhuis et al. also suggests a significant synergistic potential when GHRP-2 is combined with a GHRH analog.(8) The researchers commented that GHRH alone elicited an approximately 20‑fold increase in GH secretory‑burst mass over baseline, whereas GHRP‑2 alone drove an even larger, roughly 47‑fold augmentation in pulse size. But when both peptides were evaluated together at maximally supportive concentration, the GH response rose to about a 54‑fold increase above saline, modestly exceeding the total implications of either agent on its own.

This pattern suggests that, although each secretagogue may independently trigger a pronounced GH surge, their combined exposure to research models may further support pituitary output by an additional 10–15%. This raises the possibility of an additive or mildly synergistic interaction at the level of somatotroph stimulation. Therefore, there is a clear synergistic action when GHRP-2 is evaluated simultaneously with GHRH, from which CJC-1295 is derived. Further research is needed to investigate whether the same synergism applies to a CJC-1295 and GHRP-2 combination.

You can find CJC-1295 & GHRP-2 Blend for sale with 99% purity, on our website (available for research use only).

NOTE: These products are intended for laboratory research use only. This peptide is not intended for personal use. Please review and adhere to our Terms and Conditions before ordering.

References:

Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669.

Berlanga-Acosta J, Abreu-Cruz A, Herrera DGB, Mendoza-Marí Y, Rodríguez-Ulloa A, García-Ojalvo A, Falcón-Cama V, Hernández-Bernal F, Beichen Q, Guillén-Nieto G. Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidence Supporting Their Cytoprotective Effects. Clin Med Insights Cardiol. 2017 Mar 2;11:1179546817694558. doi: 10.1177/1179546817694558. PMID: 28469491; PMCID: PMC5392015.

Culhane KJ, Liu Y, Cai Y, Yan EC. Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors. Front Pharmacol. 2015 Nov 5;6:264. doi: 10.3389/fphar.2015.00264. PMID: 26594176; PMCID: PMC4633518.

Yin Y, Li Y, Zhang W. The growth hormone secretagogue receptor: its intracellular signaling and regulation. Int J Mol Sci. 2014 Mar 19;15(3):4837-55. doi: 10.3390/ijms15034837. PMID: 24651458; PMCID: PMC3975427.

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.

Bowers, C. Y., Granda, R., Mohan, S., Kuipers, J., Baylink, D., & Veldhuis, J. D. (2004). Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women. The Journal of clinical endocrinology and metabolism, 89(5), 2290–2300. https://doi.org/10.1210/jc.2003-031799

Veldhuis, J. D., Keenan, D. M., Bailey, J. N., Adeniji, A. M., Miles, J. M., & Bowers, C. Y. (2009). Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp. The Journal of clinical endocrinology and metabolism, 94(6), 2137–2143. https://doi.org/10.1210/jc.2009-0136

Veldhuis JD, Keenan DM. Secretagogues govern GH secretory-burst waveform and mass in healthy eugonadal and short-term hypogonadal men. Eur J Endocrinol. 2008 Nov;159(5):547-54. doi: 10.1530/EJE-08-0414. Epub 2008 Aug 14. Erratum in: Eur J Endocrinol. 2008 Dec;159(6):841. PMID: 18703567; PMCID: PMC2680123.

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

Latest Blog Articles

Thymogen Potential in Immune Cell Regulation

CJC-1295 & Hexarelin Blend Potential for Growth Hormone Signaling Stimulation

Oxytocin Actions On Neuronal Circuits in Different Mammalian Research Models

Kisspeptin 45-54 Peptide Interactions with Hypothalamic and Neuronal Cells

T-31 Peptide Interactions with Cellular Aging, Renewal, and Stress Pathways

CONNECTED / MODULES

Post-session references

Selected from shared article topics. Source links are retained where available.

01

Handling & safety lane

Source-derived education, not individual medical guidance or an instruction to dose.

DOSAGE SOURCE

Dosage Protocols

No FDA-approved dosing guidelines exist for CJC-1295. The following protocols are derived from clinical research and community reports.
STORAGE

Preventing Degradation: Best Practices for Handling and Storage

Minimizing CJC-1295 degradation reconstituted isn't rocket science, but it does demand meticulous attention to detail. Here’s what we recommend based on years of expertise in peptide synthesis and supply: Use High-Quality Solvents: Always use sterile, pharmaceutical-grade water for injection or Bacteriostatic Reconstitution Water (bac) for reconstitution. These are designed to minimize contaminants and maintain a stable pH. Don't cut corners here; it’s a false economy. Aseptic Technique: Handle peptides in a clean, sterile environment. Use sterile needles, syringes, and vials. This prevents microbial contamination and the introduction of other impurities that could accelerate degradation. Our team trains extensively on these protocols, and we encourage our research partners to do the same. Optimal Storage Temperatures: For short-term storage (a few days to a week), refrigeration at 2-8°C is generally acceptable. For longer periods, freezing at -20°C or even -80°C is highly recommended. Remember our advice on aliquoting to avoid repeated freeze-thaw cycles. Protect from Light: Store reconstituted peptides in opaque or amber vials, or wrap clear vials in aluminum foil to shield them from light. Minimize Agitation: Vigorous shaking can introduce air, leading to oxidation, and can also cause aggregation. Gentle swirling is usually sufficient to dissolve peptides. Avoid Air Exposure: Oxygen is another catalyst for degradation. When possible, store vials with minimal headspace, or…
02

Question drills

Open a question for its connected answer.

01What If Recovery Results Appear Slower Than Expected After Four Weeks?+

Verify dosing accuracy and reconstitution protocol first. CJC-1295 (DAC) is typically dosed at 1–2mg per week; underdosing below 0.5mg weekly produces subtherapeutic IGF-1 elevation. Reconstitution with bacteriostatic water must preserve sterility. Contamination or improper pH can denature the peptide structure, rendering it inactive despite correct dosing volume. If dosing is confirmed accurate, assess training stimulus and protein intake. IGF-1 signaling is permissive, not causative; without adequate mechanical tension (resistance training) or substrate availability (1.6–2.2g protein per kg body weight), downstream anabolic pathways remain unstimulated even with elevated IGF-1.

SOURCE / realpeptides.co ↗
02What If I Miss a Weekly CJC-1295 Injection by Three Days?+

Administer the missed dose as soon as you remember if fewer than four days have passed since the scheduled injection, then resume your regular weekly schedule from that new administration date. If more than four days late, skip the missed dose and continue with your next scheduled injection to avoid overlapping elevated GH periods. Missing a single dose creates a temporary dip in IGF-1 levels but doesn't erase prior progress. Recomposition timelines simply extend by the duration of the gap.

SOURCE / realpeptides.co ↗
03What If My IGF-1 Doesn't Increase After Four Weeks on 50mcg Twice Weekly?+

Increase to 75mcg per injection and retest at week 6. Non-response at 50mcg suggests either lower-than-average hepatic GH receptor expression or interference from elevated cortisol (chronic stress, inadequate sleep, or overtraining all blunt GH receptor sensitivity). If IGF-1 remains below 180 ng/mL at 75mcg twice weekly, the issue isn't dose. Investigate sleep quality, cortisol rhythm, and thyroid function (subclinical hypothyroidism blunts GH-to-IGF-1 conversion). Adding MK 677 as a ghrelin mimetic can amplify the signal if pituitary responsiveness is the limiting factor.

SOURCE / realpeptides.co ↗
04What If I Used Sterile Water Instead of Bacteriostatic Water?+

The peptide will degrade within 72–96 hours even under refrigeration. Bacteriostatic water contains 0.9% benzyl alcohol, which prevents bacterial growth in multi-dose vials and stabilises pH. Sterile water lacks this preservative. Meaning each time you insert a needle, you introduce potential contamination that accelerates degradation. Additionally, sterile water's neutral pH (6.5–7.5) is less stable for peptide storage than bacteriostatic water's buffered range. If you've already reconstituted with sterile water, use the entire vial within 3–4 days or discard it. For all future reconstitutions, use only bacteriostatic water.

SOURCE / realpeptides.co ↗
05What If Two Vials from the Same Supplier Reconstitute Differently?+

This indicates inconsistent manufacturing. A hallmark of counterfeit or low-quality peptide production. Batch-to-batch variation in reconstitution behavior means the supplier lacks process control during lyophilization. Pharmaceutical-grade peptide synthesis produces identical physical properties across every vial because lyophilization parameters are tightly controlled. If you observe this pattern, discontinue use immediately and switch to a supplier with documented GMP compliance.

SOURCE / realpeptides.co ↗
03

Evidence cooldown

Research context and source excerpts for a slower second read.

RESEARCH

CJC-1295 for Joint Pain Research Evidence: Study Design Gaps

If you're designing a protocol around CJC-1295 and joint pathology, you're navigating methodological challenges that existing studies haven't solved. First: dose extrapolation. Rodent studies used 100–200µg/kg bodyweight; the equivalent human dose would be 7–14mg per injection based on allometric scaling. Far higher than the 1–2mg doses used in current human GH elevation trials. Whether higher doses improve joint outcomes or simply increase side effect risk (water retention, carpal tunnel symptoms, insulin resistance) is unknown. Second: outcome measurement. Joint pain is subjective, influenced by placebo response rates that exceed 30% in osteoarthritis trials. Structural endpoints like cartilage thickness require high-resolution MRI with consistent imaging protocols across timepoints. Expensive and operator-dependent. Biomarkers offer an alternative: serum CTX-II (a cartilage degradation marker) and COMP (cartilage oligomeric matrix protein) correlate with disease progression, but whether CJC-1295 shifts these markers in humans hasn't been tested. The 2017 rat study measured tissue histology post-mortem. Not an option in human trials. Third: trial duration. Cartilage turnover in humans occurs over months to years, not weeks. The 2014 GH meta-analysis required 12–24 months to detect structural changes. Shorter trials measuring only pain reduction face the confound of natural symptom fluctuation and regression to the mean. Properly powered trials need 200+ participants per arm to detect clinically meaningful differences. A resource commitment no peptide manufacturer has funded for CJC-1295 specifically. These gaps don't invalidate CJC-1295 as a research tool. They define the frontier. Labs working with CJC-1295 Ipamorelin 5MG 5MG combination protocols are exploring synergistic GH release patterns that might optimise tissue repair windows without the methodological clarity of completed Phase 3 trials.

RESEARCH

Is there a risk of desensitization with CJC-1295 use in research?

While not common with appropriate protocols, excessive or prolonged high-dose administration in research could theoretically lead to GHRH receptor desensitization. This highlights the importance of adhering to precise, evidence-based research protocols.

05

Product & matchup locker

Linked catalog and comparison files.

Comparison

CJC-1295 Bacteriostatic Water Ratio Comparison

2mg 2mL 1000mcg/mL 0.10mL (10 units) High. Standard insulin syringe resolution Standard protocol. Maintains measurement accuracy across dose ranges 50–200mcg 5mg 5mL High. Consist…

Continue reading

Related articles